Miraculins Inc.

Miraculins Inc.

January 11, 2005 09:41 ET

Miraculins Announces Start of Breast Cancer Study




JANUARY 11, 2005 - 09:41 ET

Miraculins Announces Start of Breast Cancer Study

WINNIPEG, MANITOBA--(CCNMatthews - Jan. 11, 2005) - Miraculins Inc. (TSX
VENTURE:MOM), a biotechnology company engaged in the discovery and
development of products for select cancers, is pleased to announce the
launch of its breast cancer study program with the initiation of an
agreement with Radiant Research.

The study will apply Miraculins' proprietary BEST™ platform to
clinical samples collected on behalf of the Company by Radiant Research,
a comprehensive clinical research company that provides Phase I-IV
clinical drug development services to the biopharmaceutical and medical
device industry. The study is designed to discover and validate protein
and peptide biomarkers for improving the diagnosis of breast cancer. The
program represents a new area of study for Miraculins and complements
the Company's focus on developing improved methods for the diagnosis of
prostate cancer.

"The BEST™ platform is a valuable tool for the discovery of targets
of clinical significance. We are eager to demonstrate its ability in
breast cancer", stated Dr. Jim Charlton, President of Miraculins Inc.
"There are many parallels to be drawn between breast and prostate
cancer. Aside from the high incidence rates, the most obvious parallel
is the deficiency in current diagnostic methods, which have very high
false positive rates for these two cancers. Miraculins is vigorously
pursuing new methods that will fill the critical need for more accurate

In 2004, it was expected there would be greater than 250,000 breast
cancer diagnoses in North America, making it the most prevalent non-skin
cancer among women. Women in the United States have an estimated 1 in 7
chance of developing invasive breast cancer in their lifetime. A breast
cancer tumour can exist for six to ten years before it can be detected
by mammography, the current standard for diagnosing breast cancer.
Furthermore, the false positive rate for mammography is approximately
10%; thus, if a woman has 10 mammograms over her lifetime, she has a
greater than 50% chance of at least one false positive diagnosis. Of
further concern, mammography is less effective in younger women, the
group in which the breast cancer survival rate is the lowest. However,
when breast cancer is detected early the five-year survival rate exceeds

In mid-December Miraculins announced positive interim results from its
prostate cancer discovery program. Preliminary analysis of a set of
samples from the study, showed that by using Miraculins' approach, the
concurrent analysis of clinical factors and biological data had a
sensitivity and selectivity of greater than 90% respectively, and
provided a significant improvement over the Prostate Specific Antigen
(PSA) test alone. The prostate cancer study represents the lead project
for Miraculins, now complemented by the Company's breast cancer project.
The Company continues to evaluate opportunities to expand its focus and
initiate studies in additional disease conditions.

About Radiant Research

Based near Seattle, Wash., Radiant Research (radiantresearch.com) is a
comprehensive clinical research company that provides Phase I-IV
clinical drug development services to the biopharmaceutical and medical
device industry. Radiant is comprised of more than 50 wholly-owned
premier clinical research sites nationwide, employing over 1,000
research professionals exclusively focused on providing professional,
high-quality comprehensive clinical research services. In the past four
years, Radiant has conducted more than 8,400 clinical trials across 18
therapeutic specialties. Radiant's client list includes every major
pharmaceutical company and contract research organization as well as
many biotechnology and medical device companies.

About Miraculins Inc.

Miraculins is a biotechnology company focused on research and
development using its proprietary BEST™ platform for the screening
and identification of target proteins and peptides related to diseases.
The Company is developing products for the diagnosis and treatment of
select cancers.

Certain information contained in this press release may be
forward-looking and is subject to risks and uncertainties. Although the
Company believes that the expectations contained herein are reasonable,
it can give no assurances such forward-looking statements will prove
correct. Information is provided from sources deemed to be reliable.


Contact Information

    Miraculins Inc.
    Michael Coutts
    Investor Relations
    (204) 487-2328
    (204) 488-9823 (FAX)
    Radiant Research
    Michael K. Lester
    Chief Executive Officer
    (425) 468-6200
    The TSX Venture Exchange has neither approved nor disapproved the
    contents of this press release.